Failed Trial of Experimental Drug for Heart Attack Prevention

An experimental drug intended to prevent heart attacks and strokes did not meet expectations in a recent study. Researchers reported the disappointing outcome on Saturday. The drug aimed to lower a specific blood particle linked to cardiovascular events but failed to demonstrate protective benefits.

Study Details

Steven Nissen, a cardiologist at the Cleveland Clinic, led the study. He expressed surprise at the results, noting the urgent need for new cardiovascular therapies. Heart disease remains the leading cause of death in developed nations, prompting the search for additional risk-reducing options.

The study focused on individuals who already follow health guidelines. Despite maintaining low cholesterol, good diet, healthy weight, and regular exercise, many still experience heart attacks and strokes. Researchers hoped to help such patients.

Lipoprotein(a) and Heart Disease

Many of the target patients have high levels of lipoprotein(a) or Lp(a), a protein believed to raise heart disease risk. Approximately 20% of the global population faces this issue. Scientists have long sought a way to lower these levels.

In recent years, several companies developed drugs capable of reducing Lp(a). The study involved 8,350 adults with heart disease, giving them either a placebo or pelacarsen, a drug that cuts Lp(a). While Lp(a) levels dropped by 78%, this did not translate into reduced cardiovascular complications over five years.

Implications and Future Research

The results were disappointing for many in the medical community. Harlan Krumholz, a Yale University cardiologist, described the findings as unexpected, given the high expectations surrounding Lp(a)-lowering drugs.

There is speculation about why the drug failed. It might be that high Lp(a) levels do not directly cause heart attacks and strokes, but rather indicate another risk factor. Alternatively, the treatment duration may have been insufficient, or the intervention could need to start earlier.

Some experts suggest that Lp(a)-lowering drugs may only benefit patients with higher baseline Lp(a) levels. Also, controlling other blood factors like blood pressure and cholesterol might be necessary for effectiveness. The drug, pelacarsen, might also lack efficacy where other Lp(a)-lowering drugs could succeed.

Other companies, including Amgen and Eli Lilly, are conducting trials on different Lp(a)-lowering medications. Results from these will be available in the coming years. Karol Watson from UCLA believes the study’s findings do not signal an end but rather a beginning for further exploration.